My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 661

    1.

    Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.

    Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, Engers R, Florl AR, Wullich B, Rahnenführer J.

    Mol Cancer. 2007 Feb 5;6:14.PMID: 17280610 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma.

    Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH, Visakorpi T.

    Genes Chromosomes Cancer. 2002 Sep;35(1):58-65.PMID: 12203790 [PubMed - indexed for MEDLINE]Related articles

    3.

    Downregulation of several fibulin genes in prostate cancer.

    Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Müller M, Schulz WA.

    Prostate. 2007 Dec 1;67(16):1770-80.PMID: 17929269 [PubMed - indexed for MEDLINE]Related articles

    4.

    Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.

    Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH.

    J Pathol. 2007 Feb;211(3):269-77.PMID: 17139617 [PubMed - indexed for MEDLINE]Related articles

    5.

    Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.

    Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA.

    Cancer Biol Ther. 2007 Sep;6(9):1403-12.PMID: 18637271 [PubMed - indexed for MEDLINE]Related articles

    6.

    DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.

    Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG.

    Cancer Res. 2008 Nov 1;68(21):8954-67.PMID: 18974140 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.

    Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE.

    Cancer Res. 2002 Sep 15;62(18):5325-35.PMID: 12235003 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    High frequency of alterations in DNA methylation in adenocarcinoma of the prostate.

    Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA.

    Prostate. 1999 May 15;39(3):166-74.PMID: 10334105 [PubMed - indexed for MEDLINE]Related articles

    9.

    Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation.

    Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA.

    Br J Cancer. 2004 Aug 31;91(5):985-94.PMID: 15292941 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer.

    Liu JW, Nagpal JK, Jeronimo C, Lee JE, Henrique R, Kim MS, Ostrow KL, Yamashita K, van Criekinge V, Wu G, Moon CS, Trink B, Sidransky D.

    Prostate. 2008 Mar 1;68(4):418-26.PMID: 18196513 [PubMed - indexed for MEDLINE]Related articles

    11.

    Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.

    Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Müller M, Jung V, Rahnenführer J, Schulz WA.

    Cancer Genomics Proteomics. 2008 Mar-Apr;5(2):123-36.PMID: 18460741 [PubMed - indexed for MEDLINE]Related articles

    12.

    Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model.

    Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR.

    Mol Cancer Res. 2008 Aug;6(8):1365-74. Epub 2008 Jul 30.PMID: 18667590 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.

    Sørensen KD, Borre M, Ørntoft TF, Dyrskjøt L, Tørring N.

    Int J Cancer. 2008 Feb 1;122(3):509-19.PMID: 17943724 [PubMed - indexed for MEDLINE]Related articles

    14.

    DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.

    Reyes I, Tiwari R, Geliebter J, Reyes N.

    Biomedica. 2007 Jun;27(2):190-203. Epub 2007 Aug 21.PMID: 17713630 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Alterations of the retinoblastoma gene in human prostate adenocarcinoma.

    Tricoli JV, Gumerlock PH, Yao JL, Chi SG, D'Souza SA, Nestok BR, deVere White RW.

    Genes Chromosomes Cancer. 1996 Feb;15(2):108-14.PMID: 8834174 [PubMed - indexed for MEDLINE]Related articles

    16.

    Methylation of the ASC gene promoter is associated with aggressive prostate cancer.

    Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS.

    Prostate. 2006 May 15;66(7):687-95.PMID: 16425203 [PubMed - indexed for MEDLINE]Related articles

    17.

    Increased expression of the metastasis-associated gene Ehm2 in prostate cancer.

    Wang J, Cai Y, Penland R, Chauhan S, Miesfeld RL, Ittmann M.

    Prostate. 2006 Nov 1;66(15):1641-52.PMID: 16927306 [PubMed - indexed for MEDLINE]Related articles

    18.

    In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.

    Perry AS, Loftus B, Moroose R, Lynch TH, Hollywood D, Watson RW, Woodson K, Lawler M.

    Br J Cancer. 2007 May 21;96(10):1587-94. Epub 2007 Apr 24.PMID: 17453001 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Integrative analysis of genomic aberrations associated with prostate cancer progression.

    Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.

    Cancer Res. 2007 Sep 1;67(17):8229-39.PMID: 17804737 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer.

    Chen C, Bhalala HV, Vessella RL, Dong JT.

    Prostate. 2003 May 1;55(2):81-8.PMID: 12661032 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination
    Write to the Help Desk